All In Biotech

Drug Trial Radar · NCT02414854

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

Last checked: Nov 20, 2026Latest source record: Oct 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,902 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,902

Actual

Start

Apr 27, 2015

Primary completion

Jul 29, 2017

Study completion Nov 23, 2017

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Apr 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life. * To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.

Conditions

  • Asthma

Interventions

  • DupilumabDrug

    Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

  • PlaceboDrug

    Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

  • Inhaled corticosteroid (ICS) therapyDrug

    Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)

  • Albuterol/SalbutamolDrug

    Oral inhalation as needed

  • Levalbuterol/LevosalbutamolDrug

    Oral inhalation as needed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) PopulationTime frame: Baseline to Week 52
  2. Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT PopulationTime frame: Baseline, Week 12

Locations

389 sites in 22 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840047

    Birmingham, Alabama

  • Investigational Site Number 840056

    Flagstaff, Arizona

  • Investigational Site Number 840099

    Gilbert, Arizona

  • Investigational Site Number 840087

    Scottsdale, Arizona

  • Investigational Site Number 840132

    Little Rock, Arkansas

  • Investigational Site Number 840109

    Bakersfield, California

  • Investigational Site Number 840052

    Costa Mesa, California

  • Investigational Site Number 840116

    Fresno, California

  • Investigational Site Number 840045

    Long Beach, California

  • Investigational Site Number 840011

    Los Angeles, California

  • Investigational Site Number 840061

    Los Angeles, California

  • Investigational Site Number 840097

    Los Angeles, California

  • Investigational Site Number 840019

    Mission Viejo, California

  • Investigational Site Number 840125

    Newport Beach, California

  • Investigational Site Number 840041

    North Hollywood, California

  • Investigational Site Number 840036

    Redwood City, California

  • Investigational Site Number 840020

    Rolling Hills Estates, California

  • Investigational Site Number 840074

    Roseville, California

  • Investigational Site Number 840021

    San Jose, California

  • Investigational Site Number 840004

    Centennial, Colorado

  • Investigational Site Number 840025

    Colorado Springs, Colorado

  • Investigational Site Number 840034

    Denver, Colorado

  • Investigational Site Number 840130

    Denver, Colorado

  • Investigational Site Number 840102

    New Haven, Connecticut

  • Investigational Site Number 840037

    Aventura, Florida

  • Investigational Site Number 840018

    Boynton Beach, Florida

  • Investigational Site Number 840105

    Brandon, Florida

  • Investigational Site Number 840092

    Clearwater, Florida

  • Investigational Site Number 840122

    Hialeah, Florida

  • Investigational Site Number 840053

    Loxahatchee Groves, Florida

  • Investigational Site Number 840069

    Miami, Florida

  • Investigational Site Number 840123

    Ocala, Florida

  • Investigational Site Number 840071

    Ocala, Florida

  • Investigational Site Number 840115

    Ocoee, Florida

  • Investigational Site Number 840055

    Sarasota, Florida

  • Investigational Site Number 840114

    South Miami, Florida

  • Investigational Site Number 840048

    Tampa, Florida

  • Investigational Site Number 840084

    Gainesville, Georgia

  • Investigational Site Number 840044

    Savannah, Georgia

  • Investigational Site Number 840079

    Twin Falls, Idaho

Showing 40 of 389 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.